Anti-IL-3 Antibodies for SLE Renal Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatment options for systemic lupus erythematosus (SLE) are modestly effective, often have severe side effects, and do not adequately address organ involvement, particularly kidney issues, with a need for alternative treatments that are less immunosuppressive and have fewer side effects.
Innovation Solution
The use of anti-IL-3 antibodies or IL-3 binding fragments that specifically target and neutralize interleukin-3 (IL-3), reducing its activity and thereby mitigating autoimmune responses in SLE, which are administered to patients with increased IL-3 levels to decrease renal infiltration and damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If general immunosuppression treatment is used for SLE, then autoimmune responses are suppressed, but severe side effects occur including infections and tumor development
Solution Approach 1:
The patent segments the immune system by specifically targeting IL-3 and its receptor (IL-3R) pathway rather than suppressing the entire immune system. This selective approach divides the immunosuppression function into a specific component (IL-3 signaling) that can be inhibited without affecting other immune functions, thereby reducing side effects while maintaining treatment effectiveness
Solution Approach 2:
The patent uses anti-IL-3 antibodies or anti-IL-3R antibodies as intermediary molecules to block the interaction between IL-3 and its receptor. This intermediary approach prevents the harmful autoimmune responses mediated by IL-3 signaling while avoiding the need for broad immunosuppression, thus reducing side effects like infections and tumor development
2Reliability
If current immunosuppressants are used for SLE with organ involvement, then some patients respond, but less than 60% respond and relapses occur after reduction
Solution Approach 1:
The patent applies preliminary action by administering anti-IL-3 or anti-IL-3R antibodies early in the treatment course to prevent disease progression and establish sustained remission. The specific targeting of IL-3 pathway provides a strong initial therapeutic effect that maintains disease control, reducing relapse rates when treatment is reduced or stopped
3Reliability
If broad immunosuppression is used to treat SLE, then autoimmune responses are reduced, but the treatment is highly immunosuppressive affecting healthy immune functions
Solution Approach 1:
The patent segments the immune suppression function to target only the IL-3 signaling pathway specifically. By using anti-IL-3 antibodies or anti-IL-3R antibodies, the treatment selectively inhibits the pathological autoimmune responses driven by IL-3 while preserving other immune functions, thus maintaining adaptability of the healthy immune system
Solution Approach 2:
The patent applies local quality by directing the therapeutic effect specifically to IL-3-mediated autoimmune processes. The anti-IL-3 or anti-IL-3R therapy creates a localized immunomodulatory effect on the specific pathological pathway without broadly affecting other immune functions, preserving the versatility and adaptability of healthy immune responses
Data Source
Figure 1
Figure 2A~2B
Figure 2C~2D
AI summary
The present invention relates to anti-IL-3 antibodies or IL-3 binding fragments thereof for use in the treatment of an autoimmune disease selected from the group consisting of systemic lupus erythematosus and multiple sclerosis, and to pharmaceutical compositions comprising such an antibody or antibody fragment.